AstraZeneca's Klygefa Gets U.S., E.U. Approval
By Adam Whittaker
AstraZeneca's autoimmune drug Klygefa has been approved in the U.S. and the European Union to treat adults with generalized myasthenia gravis.
In separate releases Monday, the U.K. pharmaceutical company said the approvals follow Phase 3 trials that showed the drug delivered a significant and clinically meaningful improvement in quality of life, and was generally well-tolerated.
Generalized myasthenia gravis is a rare autoimmune disorder that causes reduced muscle function and severe muscle weakness.
The drug is taken once a week and is self-administered via an autoinjector.
Write to Adam Whittaker at adam.whittaker@wsj.com
(END) Dow Jones Newswires
November 16, 2026 02:34 ET (07:34 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular

5 Stocks to Buy After Earnings

7 Undervalued Stocks That Crushed Earnings

This Newly Undervalued Stock Has Plenty of Growth Ahead

Are These Riskier Bond ETFs Worth the Higher Yields?

